{
  "metadata": {
    "case_id": 57,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T17:12:59.032517",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/57_NCT01781637.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/57_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.68,
          0.18,
          0.05
        ],
        [
          0.1,
          0.7,
          0.08
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.68,
          "status": "matched",
          "ref_item": {
            "label": "omalizumab group",
            "type": "EXPERIMENTAL",
            "description": "Patients will receive omalizumab.",
            "interventionNames": [
              "Drug: Omalizumab"
            ]
          },
          "pred_item": {
            "label": "Omalizumab + Oral Immunotherapy (OIT)",
            "type": "EXPERIMENTAL",
            "description": "Subjects received omalizumab for 12 weeks followed by rapid escalation to 250 mg of peanut protein on the first day of desensitization. Patients underwent weekly up-dosing over the next 8 weeks to a maximum dose of 2000 mg. Omalizumab was continued for a total of 19 weeks, after which it was discontinued and OIT continued.",
            "interventionNames": [
              "BIOLOGICAL: Omalizumab",
              "BIOLOGICAL: Peanut Oral Immunotherapy"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.7,
          "status": "matched",
          "ref_item": {
            "label": "placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Patients will receive placebo.",
            "interventionNames": [
              "Drug: placebo"
            ]
          },
          "pred_item": {
            "label": "Placebo + Oral Immunotherapy (OIT)",
            "type": "PLACEBO_COMPARATOR",
            "description": "Subjects received placebo for 12 weeks followed by rapid escalation to 250 mg of peanut protein on the first day of desensitization. Patients underwent weekly up-dosing over the next 8 weeks to a maximum dose of 2000 mg. Placebo was continued for a total of 19 weeks. Subjects failing to reach the 250 mg dose at 19 weeks were given the option to switch to open-label omalizumab and all but one opted to cross over to treatment with omalizumab prior to completing OIT.",
            "interventionNames": [
              "DRUG: Placebo",
              "BIOLOGICAL: Peanut Oral Immunotherapy"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.94,
          0.15,
          0.2
        ],
        [
          0.2,
          0.25,
          0.82
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Omalizumab",
            "description": "subcutaneous injection",
            "armGroupLabels": [
              "omalizumab group"
            ],
            "otherNames": [
              "Xolair"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "Omalizumab",
            "description": "Humanized monoclonal anti-IgE antibody administered for 12 weeks, then continued for a total of 19 weeks during the initial phase of oral immunotherapy.",
            "armGroupLabels": [
              "Omalizumab + Oral Immunotherapy (OIT)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "placebo",
            "description": "subcutaneous injection",
            "armGroupLabels": [
              "placebo"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Placebo administered in place of omalizumab for 12 weeks, then continued for a total of 19 weeks during the initial phase of oral immunotherapy.",
            "armGroupLabels": [
              "Placebo + Oral Immunotherapy (OIT)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.2
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.2,
          "status": "matched",
          "ref_item": {
            "measure": "Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo",
            "timeFrame": "6 weeks after last dose of omalizumab/placebo"
          },
          "pred_item": {
            "measure": "Characterization of IgE and IgG peanut epitope repertoires in peanut-allergic patients undergoing oral immunotherapy",
            "description": "Identification and quantification of linear epitopes within peanut allergens recognized by IgE and IgG antibodies using AllerScan (phage immunoprecipitation sequencing). Z-scores represent enrichment of peptides compared to mock immunoprecipitation reactions. High-resolution epitope mapping achieved via saturation mutagenesis.",
            "timeFrame": "Baseline (week 0) and post-oral immunotherapy (week 52)"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 6,
      "similarity_matrix": [
        [
          0.18,
          0.1,
          0.1,
          0.12,
          0.08,
          0.07
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.18,
          "status": "matched",
          "ref_item": {
            "measure": "Pass 4000 mg OFC 12 Weeks After Last Dose of Omalizumab/Placebo",
            "timeFrame": "12 weeks after last dose of omalizumab/placebo"
          },
          "pred_item": {
            "measure": "Changes in IgE epitope diversity during oral immunotherapy",
            "description": "Number of peanut peptides recognized by IgE antibodies before and after OIT. Assessed by counting wild-type peptides with Z-score > 3.5, excluding homologous peptides from protein variants.",
            "timeFrame": "Baseline (week 0) and post-oral immunotherapy (week 52)"
          }
        }
      ]
    }
  ]
}